An interventional study of Sex Trafficking Survivor-Developed Digital Crowdsourced Intervention in HIV Testing, STI and HCV, sponsored by Columbia University. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Columbia University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 283 studies in Sexually Transmitted Diseases with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Sexually Transmitted Diseases · United States.
Among the 283 studies in Sexually Transmitted Diseases with a site in United States, this one is the 134th largest by planned enrollment of the 251 interventional ones that give a count, is one of 4 that started in 2027, is one of 190 with no phase, reaches primary completion later than 26 of the 41 other live ones, and was the 270th registered.
525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.
Browse Sexually Transmitted Diseases studies →32 of the 283 studies in Sexually Transmitted Diseases with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 15–50 · Women only
Westat · Sites in United States
Ages 13–24 · Men only · Healthy volunteers
Emory University · Sites in United States
Women only · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 13–21 · Men only · Healthy volunteers
Westat · Sites in United States
Ages 13–29 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 29 · Phase 3 15 · Phase 4 12
First in 1993; this study’s year is marked. 4 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 368 is below the median of 449 across 426 interventional studies indexed under Sexually Transmitted Diseases.
Median enrollment 400 across the 251 interventional studies, 280 across the 30 observational. Of the 227 that completed or were terminated, 76 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 283 have an industry lead sponsor. The 10 most frequent:
Columbia University is the lead sponsor of 1,136 studies on the registry; 194 are open to participants now.
Of its 182 completed or terminated interventional studies of FDA-regulated products, 150 (82%) have results posted.
Columbia University has 8 studies filed under Sexually Transmitted Diseases — fewer than ten, so there is no comparison to draw.
16 of the studies in Sexually Transmitted Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06183502Emory UniversityHIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men | 2026-11 |
| NCT07089836American Laboratory Products CompanyThis Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests. | 2026-12 |
| NCT07281599QurasenseEvaluation of the Q-Pad hrHPV Test System for Identifying Precancer | 2026-12-31 |
| NCT06844045Icahn School of Medicine at Mount SinaiPoint of Care STI Testing | 2026-12-31 |
| NCT04372875Children's National Research InstituteHealth Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 283 studies in Sexually Transmitted Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project will assess whether a digital survivor crowdsourced intervention can increase HIV/STI/HCV testing and overdose prevention kit utilization among survivors of sex trafficking living in New York City. Survivors of sex trafficking have among the highest rates of HIV/STIs/HCV and substance use disorder (SUD), yet they face substantial barriers to care, including lack of information about care and financial and logistical constraints. In addition, there is a lack of public health messaging tailored specifically for survivors of sex trafficking to meet their needs. Citizen science approaches, such as crowdsourcing (i.e., engaging groups of individuals to address public health challenges and share solutions), are scalable, cost-effective tools that can increase HIV/SUD prevention and treatment utilization. Crowdsourcing can be used to engage survivors in developing tailored messaging to promote HIV/STI/HCV testing, overdose prevention, and treatment utilization. Complementing crowdsourcing, specimen self-collection with remote HIV/STI/HCV testing and online delivery of overdose prevention kits to survivors may also increase use of needed healthcare services. Study aims are: 1) develop crowdsourced digital messages to promote HIV/STI/HCV testing uptake and utilization of overdose prevention services for substance use among sex trafficking survivors; 2) in a randomized controlled trial, to compare the survivor-crowdsourced HIV and substance use intervention to existing public health messaging among sex trafficking survivors (n=368) in New York City; and 3) assess the contribution of multi-level factors on reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) outcomes. This work will result in a digital crowdsourced intervention to increase HIV/STI/HCV testing uptake, overdose prevention kit utilization, and linkage to care among survivors of sex trafficking. This project will also result in a crowdsourcing and messaging toolkit that can be broadly distributed to public health and other agencies across the country for their use in designing messaging campaigns for survivors. Findings from this project will lay the groundwork for citizen science-developed HIV and SUD interventions for sex trafficking survivors across the US.
The investigators propose to develop and assess whether a digital survivor-crowdsourced (i.e., engaging individuals to address public health challenges and share solutions) intervention can increase testing for HIV, sexually transmitted infections (STIs), and hepatitis C virus (HCV) and the utilization of life-saving overdose prevention practices and services among survivors of sex trafficking (ST) in New York City (NYC). ST survivors have higher risk substance use (e.g., injection drug use, fentanyl) than women who are not trafficked -- >84% have used substances, with \~33% experiencing forced substance use, and \~70% a drug overdose. ST survivors have higher HIV/STI prevalence rates (up to 70%) than even non-trafficked women in sex work. Nearly 50% of survivors have branding tattoos, increasing their risk for HCV. Despite their elevated rates of HIV/STIs/HCV and substance use disorder (SUD), there is a lack of public health messaging tailored specifically for ST survivors, and much of the existing messaging is denigrating toward this population. Survivors also face substantial barriers to care, including lack of information about care access and logistical constraints. In the absence of innovative interventions tailored for this population, health problems among ST survivors will persist.
The Study's Specific Aims are:
Aim 1: Develop crowdsourced digital messages to promote HIV/STI/HCV testing uptake and utilization of overdose prevention services for substance use among female ST survivors. To achieve this aim, in partnership with our Citizen Collaborative Research Board (CCRB), the investigators will use in-depth interviews and conduct a series of designathons, launched via a national crowdsourcing open call, in which survivors ideate, prototype and present multimedia content to promote HIV/STI/HCV testing uptake and utilization of overdose prevention services among peers.
Aim 2: In a randomized controlled trial, to compare the survivor-crowdsourced HIV and substance use intervention to existing public health messaging among ST survivors (n=368) in New York City.
Hypothesis: The crowdsourced intervention will increase HIV/STI/HCV testing uptake and utilization of overdose prevention services among survivors compared to control content. The primary outcome will be online HIV/STI/HCV tests completed and online ordering of overdose prevention kits. Secondary outcomes will be linkage to HIV/STI/HCV care, PrEP, and substance use disorder (SUD) services.
Aim 3: Assess the contribution of multi-level factors on reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) outcomes. The investigators will use the PRISM framework and a mixed methods approach to assess RE-AIM outcomes via qualitative interviews, surveys, and HIV/STI/HCV testing and overdose prevention kit referral vouchers.
Hypothesis: HIV/STI/HCV testing and overdose prevention kit referral and uptake will be significantly greater among the crowdsourced intervention arm than among the control arm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The digital crowdsourced intervention will be presented to participants in the intervention arm.
Behavioral: Sex Trafficking Survivor-Developed Digital Crowdsourced Intervention
Standard informational materials about HIV/STI/HCV testing and overdose prevention currently used by Departments of Health and other health organizations will be presented to participants in the control arm.
Survivors of sex trafficking will participate in crowdsourcing contests to create digital materials to promote HIV/STI/HCV testing and use of overdose prevention kits. Entries will be judged by community and expert judges. Top entries will be selected for the digital intervention and presented to participants in the intervention arm.
HIV/STI/HCV testing uptake
The number of participants who ordered and returned a HIV/STI/HCV test kit from baseline to the 6-month follow-up. It is a dichotomous outcome (yes/no).
Time frame: From baseline to the 6 month follow-up
Overdose Prevention Kit Uptake
The number of participants who ordered an overdose prevention kit from baseline to the 6-month follow-up. It is a dichotomous outcome (yes/no).
Time frame: From baseline to the 6 month follow-up
Linkage to HIV/STI/HCV care
The number of participants who test positive for HIV/STI/HCV and who access care. It is a dichotomous outcome (yes/no).
Time frame: From baseline to the 6-month follow-up
Linkage to substance use services
The number of participants who use substances who accessed substance use services from baseline to the 6-month follow-up. It is a dichotomous outcome (yes/no).
Time frame: From baseline to the 6 month follow-up
HIV/STI stigma
Mean score change in stigma from baseline to 3 months follow-up and 6 months follow-up. Higher scores correspond to higher stigma levels.
Time frame: Baseline, 3 months, and 6 months
Substance use stigma
Mean score change in stigma from baseline to 3 months follow-up and 6-months follow-up. Higher scores correspond to higher stigma levels.
Time frame: Baseline, 3 months, and 6 months
Plan to share: Yes — Survey data from baseline and follow-up assessments will be preserved and deposited in the National Addiction and HIV Data Archive Program (NAHDAP) repository.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Final submission and release of the study data will occur within 12 months following publication of the main outcomes paper and will be available through the National Addiction and HIV Data Archive Program (NAHDAP) repository in perpetuity.
Access criteria: Data will be deposited as a restricted use dataset in NAHDAP. Investigators interested in analyzing the data must submit a request to NAHDAP and receive approval before they will be able to access the data.
No publications or documents are linked to this record.
Start is estimated for Apr 2027; primary completion for Apr 2028, 12 months later.
Of 173 non-industry interventional studies with no phase under Sexually Transmitted Diseases, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 47. This study's planned 12 months is below that.
Counting every sponsor, half of 183 studies reached it within 31 months; a quarter within 16 and three quarters within 46.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Apr 2027, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sexually Transmitted Diseases →